Annual report
3151.TEDINET S100R2L9
Period2022-04-01 → 2023-03-31
Filed2023-06-30
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100RAXF (2023-06-30).
Key figures · 152
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥579.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥577.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥537.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥562.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥559.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.5bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥2.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥6.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥693m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.4bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.9bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.1bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥7.6bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥4.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥4.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥297.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥313.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥311.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥307.7bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥329.7bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥197.2bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥213.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥100.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥100.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥103.9bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥97.2bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥96.8bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥19.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥15.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥39.2bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥3.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥8.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥18.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥549m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥4.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥408m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥92.69 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.88 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.26 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.33 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.22 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥71.54 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.63 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,911.44 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,858.86 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,863.77 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,753.07 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,704.07 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.1% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.2% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 3,719 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 3,754 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 3,696 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 3,579 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 3,627 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥5.2bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥4.9bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥2.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥4.4bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥4.1bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥4.4bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.1bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.9bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.5bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥4.4bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥4.1bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥4.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥4.1bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥1.8bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.5bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥69.2bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥69.2bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥66.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥75.1bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥86.4bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥20.9bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥22.9bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥48.3bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥46.3bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥44.4bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥43.6bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥44.3bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.2bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.4bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥83.57 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.04 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.31 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.4 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥26.32 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥32.06 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.58 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥39 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥22 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥931.75 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥868.78 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥803.59 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥793.84 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥786.68 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 69.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.9% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.3% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.2% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.0% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.4% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 61,224,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 54 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 62 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 72 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 74 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 67 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥836m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥210m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 545 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥7.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥9.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | −¥204m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥13.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥13.0bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥8.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | ¥175m |
| Medical Products Wholesalereportable segment | capex | 2022-04-01 → 2023-03-31 | ¥6.1bn |
| Medical Products Wholesalereportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.6bn |
| Medical Products Wholesalereportable segment | employees | at 2023-03-31 | 2585 pure |
| Medical Products Wholesalereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥556.5bn |
| Medical Products Wholesalereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥546.1bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥10.5bn |
| Medical Products Wholesalereportable segment | segment assets | at 2023-03-31 | ¥281.6bn |
| Medical Products Wholesalereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Pharmacy Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥57m |
| Pharmacy Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥142m |
| Pharmacy Businessreportable segment | employees | at 2023-03-31 | 494 pure |
| Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥18.4bn |
| Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥18.4bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥9m |
| Pharmacy Businessreportable segment | segment assets | at 2023-03-31 | ¥8.8bn |
| Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥106m |
| Veterinary Drugs Wholesale Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥9m |
| Veterinary Drugs Wholesale Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥17m |
| Veterinary Drugs Wholesale Businessreportable segment | employees | at 2023-03-31 | 95 pure |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥10.9bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥10.9bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment assets | at 2023-03-31 | ¥5.3bn |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥339m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥6.1bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥2.8bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥585.8bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥575.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥10.5bn |
| —segment total | segment assets | at 2023-03-31 | ¥295.7bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥592.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥579.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥13.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥305.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-04-01 → 2022-03-31 | ¥803m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥144m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥6.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥4.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥2.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥8.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | −¥131m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥11.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥11.3bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥7.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | ¥56m |
| Medical Products Wholesalereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.2bn |
| Medical Products Wholesalereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.5bn |
| Medical Products Wholesalereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥553.1bn |
| Medical Products Wholesalereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥544.2bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥8.8bn |
| Medical Products Wholesalereportable segment | segment assets | at 2022-03-31 | ¥295.5bn |
| Medical Products Wholesalereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.4bn |
| Pharmacy Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥48m |
| Pharmacy Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥144m |
| Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥18.4bn |
| Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥18.4bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥3m |
| Pharmacy Businessreportable segment | segment assets | at 2022-03-31 | ¥10.6bn |
| Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥205m |
| Veterinary Drugs Wholesale Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥112m |
| Veterinary Drugs Wholesale Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥14m |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥10.4bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥10.4bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment assets | at 2022-03-31 | ¥5.2bn |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥371m |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥3.4bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥581.9bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥573.0bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥8.8bn |
| —segment total | segment assets | at 2022-03-31 | ¥311.3bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥2.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥588.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥577.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥11.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥320.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥2.9bn |
| Medical Products Wholesalereportable segment | employees | at 2023-03-31 | 54 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,015
| Item | Context | Value | Unit |
|---|---|---|---|
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row27Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row28Member | Original text (Japanese)㈱スズケン | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row28Member | Original text (Japanese)①同業者としての情報収集のため ②該当なし ③ＡがＢを上回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row28Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row29Member | Original text (Japanese)㈱メディパルホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row29Member | Original text (Japanese)①同業者としての情報収集のため ②該当なし ③ＡがＢを上回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row29Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row30Member | Original text (Japanese)アルフレッサホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row30Member | Original text (Japanese)①同業者としての情報収集のため ②該当なし ③ＡがＢを上回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row30Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row31Member | Original text (Japanese)武田薬品工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row31Member | Original text (Japanese)①商品の確保や仕入の円滑化のため ②該当なし ③当事業年度中に売却したため、保有効果の検証はしておりません ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row31Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row32Member | Original text (Japanese)塩野義製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row32Member | Original text (Japanese)①商品の確保や仕入の円滑化のため ②該当なし ③当事業年度中に売却したため、保有効果の検証はしておりません ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row32Member | Original text (Japanese)無 | |
| Name of group company holding second largest amount of investment shares in group | CurrentYearInstant | Original text (Japanese)㈱バイタルネット | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment second largest holding company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment second largest holding company | CurrentYearDuration | Original text (Japanese)持株会の為 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)大塚ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)①商品の確保や仕入の円滑化のため ②該当なし ③ＡがＢを上回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)無(注３) | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)第一三共㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)①商品の確保や仕入の円滑化のため ②該当なし ③ＡがＢを上回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)㈱ケアネット | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)①株主間契約締結のため ②該当なし ③ＡがＢを下回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row4Member | Original text (Japanese)㈱ヤクルト本社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row4Member | Original text (Japanese)①商品の確保や仕入の円滑化のため ②該当なし ③ＡがＢを上回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row4Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)武田薬品工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)①商品の確保や仕入の円滑化のため ②該当なし ③ＡがＢを上回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)エーザイ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)①商品の確保や仕入の円滑化のため ②該当なし ③ＡがＢを上回っております ④持株会のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)キョーリン製薬ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)①商品の確保や仕入の円滑化のため ②該当なし ③ＡがＢを上回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)無(注４) | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)㈱ほくやく・竹山ホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)①取引関係の維持・強化及び同業者としての情報収集のため ②業務提携契約締結のため ③ＡがＢを下回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)無(注５) | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)ファーマライズホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)①株主間契約締結のため ②該当なし ③ＡがＢを上回っております ④該当なし | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)久光製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)①商品の確保や仕入の円滑化のため ②該当なし ③ＡがＢを上回っております ④持株会のため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row11Member | Original text (Japanese)明治ホールディングス㈱ |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |